Journal article
Sarcopenia in daily practice: assessment and management.
- Beaudart C Department of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liège, Belgium. c.beaudart@ulg.ac.be.
- McCloskey E Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
- Bruyère O Department of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liège, Belgium.
- Cesari M Gérontopôle, University Hospital of Toulouse, Toulouse, France.
- Rolland Y Gérontopôle of Toulouse, University of Toulouse III, CHU Purpan, Toulouse, France.
- Rizzoli R Service of Bone Diseases, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.
- Araujo de Carvalho I World Health Organization, Geneva, Switzerland.
- Amuthavalli Thiyagarajan J World Health Organization, Geneva, Switzerland.
- Bautmans I Gerontology and Frailty in Ageing Research Department, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Bertière MC Centre de Recherche et d'information Nutritionnelles, Paris, France.
- Brandi ML Department of Surgery and Translational Medicine, University of Florence, viale Pieraccini 6, 59139, Florence, Italy.
- Al-Daghri NM Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia.
- Burlet N Department of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liège, Belgium.
- Cavalier E Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, Bât B35, 4000, Liège, Belgium.
- Cerreta F Human Medicines Research and Development Support Division, Scientific Advice, London, UK.
- Cherubini A Geriatrics and Geriatric Emergency Care, IRCCS-INRCA, Ancona, Italy.
- Fielding R Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, USA.
- Gielen E Department of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.
- Landi F Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart Rome, Milano, Italy.
- Petermans J Geriatric Department, CHU Sart-Tilman, Bât B35, 4000, Liège, Belgium.
- Reginster JY Department of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liège, Belgium.
- Visser M Department of Health Sciences, VU University Amsterdam, Amsterdam, Netherlands.
- Kanis J Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
- Cooper C MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, England, UK.
- 2016-10-08
Published in:
- BMC geriatrics. - 2016
Assessment
Daily practice
Management
Sarcopenia
Tools
Absorptiometry, Photon
Accidental Falls
Aged
Aging
Disability Evaluation
Exercise Test
Humans
Muscle Strength
Organ Size
Primary Health Care
Risk Assessment
Sarcopenia
Surveys and Questionnaires
English
BACKGROUND
Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice.
METHODS
This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations.
RESULTS
This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions. Development of a number of pharmacological interventions is also in progress.
CONCLUSIONS
Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.
Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to be accurate and reliable in investigational settings, many are not easily applied to daily practice.
METHODS
This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were afterwards organized for the whole group to make amendments and discuss further recommendations.
RESULTS
This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire, the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered and involve the combination of both resistance and endurance based activity programmes with or without dietary interventions. Development of a number of pharmacological interventions is also in progress.
CONCLUSIONS
Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing them to the risk of disability will become particularly important in the near future.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s12877-016-0349-4
- PMID 27716195
- Persistent URL
- https://sonar.ch/global/documents/194343
Statistics
Document views: 23
File downloads: